Literature DB >> 10439772

Methylene blue, a soluble guanylyl cyclase inhibitor, reduces the sevoflurane minimum alveolar anesthetic concentration and decreases the brain cyclic guanosine monophosphate content in rats.

E Masaki1, I Kondo.   

Abstract

UNLABELLED: The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signal pathway plays an important role in anesthetic and analgesic effects. We sought to determine the involvement of inhibition of soluble guanylyl cyclase (sGC) in the anesthetic mechanism and site of action of volatile anesthetics. We examined the effect of intracerebroventricular (ICV) administration of methylene blue (MB), a sGC inhibitor, on the minimum alveolar anesthetic concentration (MAC) of sevoflurane and the brain cGMP content in rats in vivo. We also investigated the effect of sevoflurane on NO-stimulated sGC activity in vitro. The rats were divided into three groups. After the ICV administration of MB, sevoflurane MAC and brain cGMP contents were measured in the first group and the second group, respectively. In the third group, brain cGMP contents were determined after sevoflurane anesthesia without the ICV administration of MB to examine the direct effect of sevoflurane on brain cGMP contents. MB significantly decreased sevoflurane MAC and brain cGMP content in a dose-dependent manner. Sevoflurane itself also dose-dependently decreased cGMP contents in brain in vivo and inhibited the NO-stimulated sGC activity in vitro. These results suggest that the inhibition of the NO-cGMP signal pathway at the sGC level could be involved in anesthetic or analgesic effects, and the inhibitory effect of sevoflurane on sGC would be one of the sites of action of this anesthetic. IMPLICATIONS: Because the nitric oxide-cyclic guanosine monophosphate signal pathway mediates nociception and the site of action of halogenated volatile anesthetics in uncertain, we examined the possible involvement of inhibition of soluble guanylyl cyclase in the anesthetic mechanism. The inhibitory effect of sevoflurane on soluble guanylyl cyclase could be one of sites of this anesthetic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10439772     DOI: 10.1097/00000539-199908000-00045

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements.

Authors:  A M Bester; B H Harvey
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

Review 2.  Intraoperative adjuncts in surgery for primary hyperparathyroidism.

Authors:  Barney J Harrison; Frederic Triponez
Journal:  Langenbecks Arch Surg       Date:  2009-07-10       Impact factor: 3.445

Review 3.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

4.  Sensitivity to Sevoflurane anesthesia is decreased in mice with a congenital deletion of Guanylyl Cyclase-1 alpha.

Authors:  Yasuko Nagasaka; Martin Wepler; Robrecht Thoonen; Patrick Y Sips; Kaitlin Allen; Jan A Graw; Vincent Yao; Sara M Burns; Stefan Muenster; Peter Brouckaert; Keith Miller; Ken Solt; Emmanuel S Buys; Fumito Ichinose; Warren M Zapol
Journal:  BMC Anesthesiol       Date:  2017-06-14       Impact factor: 2.217

5.  Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer.

Authors:  Solomon Oladapo Rotimi; Oluwakemi Anuoluwapo Rotimi; Abdulkadir Ayo Salako; Paul Jibrin; Jelili Oyelade; Emeka E J Iweala
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244

6.  Intracerebroventricular administration of nitric oxide-sensitive guanylyl cyclase inhibitors induces catalepsy in mice.

Authors:  M B Echeverry; M L Salgado; F R Ferreira; C A da-Silva; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2007-06-26       Impact factor: 4.415

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.